Novo Nordisk A/S (NOVOBN.MX)
| Previous Close | 2,661.00 |
| Open | 0.00 |
| Bid | 2,670.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 2,661.00 - 2,661.00 |
| 52 Week Range | 1,356.97 - 2,708.33 |
| Volume | |
| Avg. Volume | 1,861 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | 42.86 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
Bagsværd, Denmark, 26 June 2024 – Novo Nordisk today announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7 billion related to the intangible asset ocedurenone in the second quarter of 2024. Novo Nordisk acquired ocedurenone from KBP Biosciences PTE., Ltd. in 2023. The phase 3 lead indication trial CLARION-CKD, which investigated ocedurenone in patients with uncontrolled hypertension and advanced chronic ki
- GlobeNewswire
Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline
In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD 6.8 billion towards production, a significant increase from the previous year's investment of USD 3.9 billion*. Bagsværd, Denmark, 24 June 2024 – Novo Nordisk today announced plans to invest 4.1 billion US dollars (approx 27 billion Danish kroner) to build a second fill and finishing manufacturing facility in Clayton, North Carolina, and grow its ability to produce current and future injectable treatments for pe
- GlobeNewswire
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 24 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiat
